JP2017509323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509323A5 JP2017509323A5 JP2016549449A JP2016549449A JP2017509323A5 JP 2017509323 A5 JP2017509323 A5 JP 2017509323A5 JP 2016549449 A JP2016549449 A JP 2016549449A JP 2016549449 A JP2016549449 A JP 2016549449A JP 2017509323 A5 JP2017509323 A5 JP 2017509323A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- binding molecule
- molecule according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 43
- 239000012634 fragment Substances 0.000 claims 19
- 235000001014 amino acid Nutrition 0.000 claims 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 7
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 6
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 6
- 239000000710 homodimer Substances 0.000 claims 6
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 5
- 230000004927 fusion Effects 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 101100425758 Mus musculus Tnfrsf1b gene Proteins 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 101150111783 NTRK1 gene Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 102000046917 human NGF Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934828P | 2014-02-02 | 2014-02-02 | |
| US61/934,828 | 2014-02-02 | ||
| PCT/EP2015/052098 WO2015114150A1 (en) | 2014-02-02 | 2015-02-02 | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020065513A Division JP7074792B2 (ja) | 2014-02-02 | 2020-04-01 | ＮＧＦアンタゴニストドメインおよびＴＮＦαアンタゴニストドメインから構成されるキメラタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017509323A JP2017509323A (ja) | 2017-04-06 |
| JP2017509323A5 true JP2017509323A5 (enExample) | 2018-03-08 |
| JP6687526B2 JP6687526B2 (ja) | 2020-04-22 |
Family
ID=52440681
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549449A Active JP6687526B2 (ja) | 2014-02-02 | 2015-02-02 | ＮＧＦアンタゴニストドメインおよびＴＮＦαアンタゴニストドメインから構成されるキメラタンパク質 |
| JP2020065513A Active JP7074792B2 (ja) | 2014-02-02 | 2020-04-01 | ＮＧＦアンタゴニストドメインおよびＴＮＦαアンタゴニストドメインから構成されるキメラタンパク質 |
| JP2022077858A Active JP7520070B2 (ja) | 2014-02-02 | 2022-05-11 | ＮＧＦアンタゴニストドメインおよびＴＮＦαアンタゴニストドメインから構成されるキメラタンパク質 |
| JP2024109298A Pending JP2024133644A (ja) | 2014-02-02 | 2024-07-08 | ＮＧＦアンタゴニストドメインおよびＴＮＦαアンタゴニストドメインから構成されるキメラタンパク質 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020065513A Active JP7074792B2 (ja) | 2014-02-02 | 2020-04-01 | ＮＧＦアンタゴニストドメインおよびＴＮＦαアンタゴニストドメインから構成されるキメラタンパク質 |
| JP2022077858A Active JP7520070B2 (ja) | 2014-02-02 | 2022-05-11 | ＮＧＦアンタゴニストドメインおよびＴＮＦαアンタゴニストドメインから構成されるキメラタンパク質 |
| JP2024109298A Pending JP2024133644A (ja) | 2014-02-02 | 2024-07-08 | ＮＧＦアンタゴニストドメインおよびＴＮＦαアンタゴニストドメインから構成されるキメラタンパク質 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9884911B2 (enExample) |
| EP (2) | EP3099713B1 (enExample) |
| JP (4) | JP6687526B2 (enExample) |
| KR (1) | KR102489452B1 (enExample) |
| CN (2) | CN118085103A (enExample) |
| AU (3) | AU2015212787B2 (enExample) |
| CA (1) | CA2938066C (enExample) |
| CY (1) | CY1123248T1 (enExample) |
| DK (1) | DK3099713T3 (enExample) |
| ES (1) | ES2784238T3 (enExample) |
| HR (1) | HRP20200477T1 (enExample) |
| HU (1) | HUE048478T2 (enExample) |
| LT (1) | LT3099713T (enExample) |
| MX (1) | MX382763B (enExample) |
| PL (1) | PL3099713T3 (enExample) |
| PT (1) | PT3099713T (enExample) |
| RS (1) | RS60156B1 (enExample) |
| RU (1) | RU2678810C2 (enExample) |
| SI (1) | SI3099713T1 (enExample) |
| SM (1) | SMT202000182T1 (enExample) |
| WO (1) | WO2015114150A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118085103A (zh) | 2014-02-02 | 2024-05-28 | 麦迪穆有限责任公司 | 用于治疗疼痛的化合物和方法 |
| US9862760B2 (en) * | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| CN111132997A (zh) | 2017-09-21 | 2020-05-08 | 默克专利有限公司 | 包含fgf-18部分的融合蛋白 |
| WO2021142573A1 (zh) * | 2020-01-13 | 2021-07-22 | 丁邦 | 一种融合蛋白及其制法和用途 |
| KR20230084199A (ko) * | 2020-09-28 | 2023-06-12 | 메디뮨 리미티드 | 통증 치료를 위한 화합물 및 방법 |
| CN114574444B (zh) * | 2020-12-01 | 2024-05-03 | 达达生物技术(北京)有限公司 | 自体纤维母细胞在制备抗类风湿关节炎药物中的应用 |
| TWI821881B (zh) * | 2021-01-29 | 2023-11-11 | 醫研生物科技有限公司 | 腫瘤壞死因子α重組抗體及其用途 |
| CN116179667A (zh) * | 2022-09-21 | 2023-05-30 | 福建中妆技术研究有限公司 | 基于斑马鱼模型中trpv1信号通路筛选皮肤疼痛舒缓原料的试剂盒及应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2315944A1 (en) * | 1997-12-24 | 1999-07-08 | Diatech Pty. Ltd. | Bifunctional molecules |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| DE19926068C1 (de) * | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| CN1684708A (zh) | 2001-05-30 | 2005-10-19 | 基因技术股份有限公司 | 抗ngf抗体用于治疗各种疾病 |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| JP4584713B2 (ja) | 2002-10-08 | 2010-11-24 | ライナット ニューロサイエンス コーポレイション | 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物 |
| US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| WO2006024497A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| NZ556157A (en) | 2005-01-24 | 2009-09-25 | Elan Pharma Int Ltd | Specific binding members for NGF |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| BRPI0811857A2 (pt) * | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
| EP2287174B8 (en) | 2008-01-18 | 2016-12-07 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibody fragments by apatite chromatography |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| AU2009268585C1 (en) * | 2008-07-08 | 2014-10-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| JP2011016676A (ja) * | 2009-07-07 | 2011-01-27 | Sumitomo Electric Ind Ltd | 窒化物半導体基板の製造方法 |
| UY32948A (es) * | 2009-10-15 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| RU2012127383A (ru) * | 2009-12-02 | 2014-01-10 | Акселерон Фарма Инк. | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
| BR112012025568A2 (pt) * | 2010-04-07 | 2017-03-28 | Abbvie Inc | proteínas de ligação ao tnf-<244>. |
| CN106432506A (zh) * | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
| ES2749349T3 (es) | 2011-11-07 | 2020-03-19 | Medimmune Llc | Proteínas de unión multiespecíficas y multivalentes y usos de las mismas |
| US20130171059A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2014106001A2 (en) * | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | Dual specific binding proteins having a receptor sequence |
| WO2014144299A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα |
| CN118085103A (zh) | 2014-02-02 | 2024-05-28 | 麦迪穆有限责任公司 | 用于治疗疼痛的化合物和方法 |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US20210009671A1 (en) | 2019-05-10 | 2021-01-14 | Medimmune Limited | Compounds and methods for treating pain |
-
2015
- 2015-02-02 CN CN202311359790.8A patent/CN118085103A/zh active Pending
- 2015-02-02 EP EP15701985.2A patent/EP3099713B1/en active Active
- 2015-02-02 CN CN201580017113.5A patent/CN106459190A/zh active Pending
- 2015-02-02 JP JP2016549449A patent/JP6687526B2/ja active Active
- 2015-02-02 EP EP19214210.7A patent/EP3696193A1/en active Pending
- 2015-02-02 US US14/612,137 patent/US9884911B2/en active Active
- 2015-02-02 HR HRP20200477TT patent/HRP20200477T1/hr unknown
- 2015-02-02 KR KR1020167023831A patent/KR102489452B1/ko active Active
- 2015-02-02 CA CA2938066A patent/CA2938066C/en active Active
- 2015-02-02 SI SI201531149T patent/SI3099713T1/sl unknown
- 2015-02-02 RU RU2016132370A patent/RU2678810C2/ru active
- 2015-02-02 PL PL15701985T patent/PL3099713T3/pl unknown
- 2015-02-02 HU HUE15701985A patent/HUE048478T2/hu unknown
- 2015-02-02 SM SM20200182T patent/SMT202000182T1/it unknown
- 2015-02-02 MX MX2016010030A patent/MX382763B/es unknown
- 2015-02-02 RS RS20200396A patent/RS60156B1/sr unknown
- 2015-02-02 ES ES15701985T patent/ES2784238T3/es active Active
- 2015-02-02 DK DK15701985.2T patent/DK3099713T3/da active
- 2015-02-02 WO PCT/EP2015/052098 patent/WO2015114150A1/en not_active Ceased
- 2015-02-02 AU AU2015212787A patent/AU2015212787B2/en active Active
- 2015-02-02 PT PT157019852T patent/PT3099713T/pt unknown
- 2015-02-02 LT LTEP15701985.2T patent/LT3099713T/lt unknown
-
2017
- 2017-12-21 US US15/849,771 patent/US10457728B2/en active Active
-
2019
- 2019-09-17 US US16/573,192 patent/US11053307B2/en active Active
-
2020
- 2020-04-01 JP JP2020065513A patent/JP7074792B2/ja active Active
- 2020-04-10 CY CY20201100338T patent/CY1123248T1/el unknown
- 2020-09-11 AU AU2020230316A patent/AU2020230316B2/en active Active
-
2021
- 2021-05-28 US US17/333,291 patent/US11897949B2/en active Active
-
2022
- 2022-05-11 JP JP2022077858A patent/JP7520070B2/ja active Active
-
2023
- 2023-12-21 AU AU2023285832A patent/AU2023285832A1/en active Pending
-
2024
- 2024-01-03 US US18/403,043 patent/US20240262902A1/en active Pending
- 2024-07-08 JP JP2024109298A patent/JP2024133644A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509323A5 (enExample) | ||
| CN111518214B (zh) | 靶向cldn18.2的双特异性抗体及其制备方法和应用 | |
| CA2903595C (en) | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use | |
| CN110305210B (zh) | 新型抗体分子、其制备方法及其用途 | |
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| JP2013515508A5 (enExample) | ||
| US20170306018A1 (en) | Bispecific antibodies against cd3epsilon and ror1 | |
| US12258371B2 (en) | Stabilized immunoglobulin domains | |
| HRP20241775T1 (hr) | Bispecifična protutijela koja se specifično vežu na pd1 i lag3 | |
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2017504578A5 (enExample) | ||
| JP2010502183A5 (enExample) | ||
| JP2014158485A5 (enExample) | ||
| IL295295A (en) | Antibodies against fcrl5 and methods of their use | |
| JP2005518789A5 (enExample) | ||
| JP2017520575A5 (enExample) | ||
| JP2019502694A5 (enExample) | ||
| JP2020524510A5 (enExample) | ||
| JP2020515277A5 (enExample) | ||
| JP2019535315A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| JP2017534296A5 (enExample) | ||
| JP2021512159A5 (enExample) | ||
| RU2016132370A (ru) | ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα | |
| CN116940598A (zh) | 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体 |